Search results
Showing results for
Professor Dame Molly Stevens joins as a Non-Executive Director and University representative. Professor Richard Hobbs also joins as a Non-Executive Director. Simon Boddie, the Chief Financial Officer of the University of Oxford, steps down.
“From the very start of Base Genomics, through our acquisition and fast growth as Exact Sciences, the BioEscalator’s continued support significantly drove us forward towards having an impact on early detection and patient care.”
Hollie Coe, Director of Operations, Exact Sciences Innovation (formerly Base Genomics) (2021)
“MoA Technology benefited greatly from putting its foundational scientific vision into practice within the bustling and innovative ecosystem of the BioEscalator. We will remember the supportive and accommodating team fondly as we embark on our next phase of growth.”
Clément Champion, Co-Founder and CSO, MoA Technology (2021)
“Being at the BioEscalator has been a key part of Alchemab’s journey and provided us with the support and capabilities we needed to enable our growth.”
Alex Leech, CEO, Alchemab Therapeutics (2021)
“The BioEscalator is more than just an innovation centre, it’s a true community. We are grateful for the time spent here and for the chance to work alongside such bright and inspiring people.”
Ana Carolina Borges, Research Scientist, Alethiomics (2025)
“It’s an incredible experience to be part of the BioEscalator community – a place that brings together innovation, collaboration and passionate people working to translate great science into real-world impact.”
Maheen Muzaffar, Specialist Research Engineer, OSPT (2026)
“Being a BioEscalator tenant offered us unique opportunities for collaboration. The open and collaborative interactions with other tenants and the BioEscalator team have been invaluable.”
Kevin Maskell, Co-Founder and CSO, Bioarchitech (2024)
“Clinical links with the University of Oxford gave us access to exceptional expertise. When we wanted to explore a new therapeutic approach, we were able to quickly consult with an expert team of oncologists and surgeons – the kind of input that is usually out of reach for a small company.”
Kevin Maskell, Co-Founder and CSO, Bioarchitech (2024)
“We loved being at the BioEscalator and being part of its community. The support and flexibility from the BioEscalator team was invaluable.”
Hollie Coe, Director of Operations, Exact Sciences Innovation (formerly Base Genomics) (2021)
“I cannot over-emphasise the value of being in an environment with other people navigating the challenges associated with the early start-up stage.”
Charlotte Casebourne, Co-Founder and CEO, Theolytics (2019)
“We had access to flexible lab space that could scale with our needs, alongside equipment and expertise at the University of Oxford that would usually be out of reach for a small company. The BioEscalator’s equipment, research services and access to new service providers all added significant value to our work.”
Kevin Maskell, Co-Founder and CSO, Bioarchitech (2024)
“Being close to our academic research labs means our staff can benefit from access to world-leading core facilities in the neighbouring academic institutes.”
Beth Psaila, Co-Founder, Alethiomics (2023)
“The facilities and support teams enabled us to focus on R&D rather than operational maintenance.”
Atherton Mutombwera, Founder and CEO, Hutano Diagnostics (2023)